Skip to content

Eloralintide ResearchScience today. A healthier tomorrow.

Ask the site

Phase 1 eloralintide, Chinese participants (NCT06916091)

Last verified How this was verified

Trial record

Trial name
Phase I, single-dose study in Chinese participants
Registry identifier
NCT06916091
Phase
Phase I
Sponsor
Eli Lilly and Company
Population
Chinese adults with obesity or overweight
Intervention
Eloralintide (LY3841136), single dose
Comparator
Placebo (investigator- and participant-blinded, randomized)
Enrollment
30
Study status
Completed (confirmed 2026-10-01 via ClinicalTrials.gov; completed 2025-09-09)
Start date
2025-04-21
Completion date
2025-09-09
Results availability
No results posted on ClinicalTrials.gov as of 2026-10-01

Primary endpoints

  • Primary: number of participants with treatment-related adverse events and serious adverse events, up to 10 weeks. Secondary: eloralintide pharmacokinetics (AUC and Cmax) (ClinicalTrials.gov, confirmed 2026-10-01)

Primary registry record

A trial registration shows that a study exists. It does not show that the compound works, is safe, or has been approved, and recruitment says nothing about the eventual result.

This single-dose Phase 1 study examined the safety, tolerability and pharmacokinetics of eloralintide in Chinese participants with obesity or overweight, compared with placebo. The registry lists one site, in Singapore.

Read with care: A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.

Study context

What the study tests

This Phase 1 study gave a single dose of eloralintide or placebo, blinded, to Chinese adults with obesity or overweight. The primary endpoint is the number of participants with treatment-related adverse events and serious adverse events, and drug-level measures are secondary. The record lists 30 participants and about 10 weeks per participant.

Who can take part

Participants were aged 21 to 65 with a BMI from 27 to 40 and a stable body weight. To qualify as Chinese, all four biological grandparents had to be of exclusive Chinese descent and born in China. People with chronic heart, liver or kidney conditions were excluded. The only listed site is in Singapore.

What the registry does not say

The study is marked completed, with primary completion on 9 September 2025, but no results are posted. A single-dose study cannot show how people respond to repeated weekly dosing, and the record registers no efficacy measure.

Source: ClinicalTrials.gov record NCT06916091, read on 2026-10-15. Registered plans can change.

References

  1. US National Library of Medicine. ClinicalTrials.gov registry records for the eloralintide clinical program. ClinicalTrials.gov. P1